Alan Wake 2 has lumbered past three million copies sold, a milestone Remedy dropped into its half-year financial report like a quiet victory lap after years of red ink and platform gripes. The investigative horror title crossed the threshold during Q2 2026, building on the two million mark it hit by the end of 2024 and the profitability it finally clawed out after an epic-funded launch that left it shackled to one storefront. That slow, deliberate climb tells the real story: critical darling status does not equal immediate commercial thunder when the biggest PC marketplace sits behind a velvet rope.

The exclusivity remains the lingering bruise. Epic Games Store exclusivity, bankrolled by the publisher that also handled development funding, continues to draw the same tired debate about lost Steam revenue and developer-friendly rhetoric that rings hollow when the numbers tell a different tale. Remedy's new CEO has already noted the studio has not fully tapped the potential of its own creations, and Alan Wake 2's trajectory—fastest seller at launch yet still taking years to recoup—stands as exhibit A. Meanwhile the company juggles Control Resonant's September launch, Max Payne remakes in full swing, and an unannounced third project, all while overall H1 revenue dipped amid heavy spending.

Remedy's back catalog got a quiet boost too, with original Control sales rising on sequel anticipation. Alan Wake 2 itself keeps accruing royalties purely from consumer sales now, no more platform deal accruals muddying the waters. It is the kind of steady, unflashy progress that rewards patient storytelling over launch-week fireworks, yet the platform question lingers like an unresolved plot thread.